TRANEXAMIC ACID

First approved in 1986

Details

Stereochemistry	ACHIRAL
Molecular Formula	C8H15NO2
Molecular Weight	157.2102
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC[C@H]1CC[C@@H](CC1)C(O)=O

InChI

InChIKey=GYDJEQRTZSCIOI-LJGSYFOKSA-N

InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-

HIDE SMILES / InChI

Molecular Formula	C8H15NO2
Molecular Weight	157.2102
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00302
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf

Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1). Tranexamic acid is used for use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
fibrinolysis 3 Target ID: GO:0042730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8731512	Inhibitor 8297		60.0 µM [IC50]
Plasminogen 6 Target ID: CHEMBL1801 Sources: http://www.drugbank.ca/drugs/DB00302 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	Inhibitor 8297		3.1 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cyclic heavy menstrual bleeding 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	Primary		Approved 8429	LYSTEDA Approved Use LYSTEDA (tranexamic acid) Tablets is an antifibrinolytic indicated for the treatment of cyclic heavy menstrual bleeding. Launch Date 1986

C_max

Value	Dose	Co-administered	Analyte	Population
16.41 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	1300 mg 3 times / day multiple, oral dose: 1300 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TRANEXAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
13.83 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	1300 mg single, oral dose: 1300 mg route of administration: Oral experiment type: SINGLE co-administered:		TRANEXAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
77.67 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	1300 mg 3 times / day multiple, oral dose: 1300 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TRANEXAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
80.19 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	1300 mg single, oral dose: 1300 mg route of administration: Oral experiment type: SINGLE co-administered:		TRANEXAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
11.08 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	1300 mg single, oral dose: 1300 mg route of administration: Oral experiment type: SINGLE co-administered:		TRANEXAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
97% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	1300 mg single, oral dose: 1300 mg route of administration: Oral experiment type: SINGLE co-administered:		TRANEXAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	Other AEs: Headache, Nasal disorder NOS... Other AEs: Headache (50.4%) Nasal disorder NOS (25.4%) Back pain (20.7%) Abdominal pain (19.8%) Musculoskeletal pain (11.2%) Arthralgia (6.9%) Muscle cramps (6.5%) Migraine (6%) Anemia (5.6%) Fatigue (5.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
1 g 4 times / day steady, oral Overdose Dose: 1 g, 4 times / day Route: oral Route: steady Dose: 1 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24434397/	unhealthy, 45 years n = 1 Health Status: unhealthy Condition: chronic kidney disease Age Group: 45 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/24434397/	Disc. AE: Convulsions generalized... AEs leading to discontinuation/dose reduction: Convulsions generalized (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/24434397/
2000 mg 1 times / day steady, intravenous Recommended Dose: 2000 mg, 1 times / day Route: intravenous Route: steady Dose: 2000 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14712363/	unhealthy, 56 years n = 1 Health Status: unhealthy Condition: emergency operation for a bleeding ulcer of the stomach and duodenum Age Group: 56 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/14712363/	Disc. AE: Blindness... AEs leading to discontinuation/dose reduction: Blindness (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/14712363/
250 mg 2 times / day steady, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: steady Dose: 250 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27206758/	unhealthy, mean 40.7 years n = 561 Health Status: unhealthy Condition: Melasma Age Group: mean 40.7 years Sex: M+F Population Size: 561 Sources: https://pubmed.ncbi.nlm.nih.gov/27206758/	Disc. AE: Deep vein thrombosis leg... AEs leading to discontinuation/dose reduction: Deep vein thrombosis leg (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/27206758/

AEs

AE	Significance	Dose	Population
Musculoskeletal pain	11.2%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Abdominal pain	19.8%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Back pain	20.7%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Nasal disorder NOS	25.4%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Fatigue	5.2%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Anemia	5.6%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Headache	50.4%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Migraine	6%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Muscle cramps	6.5%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Arthralgia	6.9%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Convulsions generalized	1 patient Disc. AE	1 g 4 times / day steady, oral Overdose Dose: 1 g, 4 times / day Route: oral Route: steady Dose: 1 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24434397/	unhealthy, 45 years n = 1 Health Status: unhealthy Condition: chronic kidney disease Age Group: 45 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/24434397/
Blindness	1 patient Disc. AE	2000 mg 1 times / day steady, intravenous Recommended Dose: 2000 mg, 1 times / day Route: intravenous Route: steady Dose: 2000 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14712363/	unhealthy, 56 years n = 1 Health Status: unhealthy Condition: emergency operation for a bleeding ulcer of the stomach and duodenum Age Group: 56 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/14712363/
Deep vein thrombosis leg	1 patient Disc. AE	250 mg 2 times / day steady, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: steady Dose: 250 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27206758/	unhealthy, mean 40.7 years n = 561 Health Status: unhealthy Condition: Melasma Age Group: mean 40.7 years Sex: M+F Population Size: 561 Sources: https://pubmed.ncbi.nlm.nih.gov/27206758/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C19 1478 CYP2E1 882 OATP1B1 788 OATP1B3 706

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDg3NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 739	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDg3NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDg3NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDg3NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMODc3In19	no [IC50 >10 uM]
CYP2E1 970	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDg3NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMODc3In19	no [IC50 >10 uM]
OATP1B1 803	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMODc3In19

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:48669	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:48669
ChemicalBook	CB1117189	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1117189
ChemicalBook	CB2948513	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2948513
ChemicalBook	CB54848494	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB54848494
MolPort	MolPort-002-512-008	https://www.molport.com/shop/molecule-link/MolPort-002-512-008
Selleck Chemicals	tranexamic-acid-transamin	http://www.selleckchem.com/products/tranexamic-acid-transamin.html
ZINC	ZINC000100071256	http://zinc15.docking.org/substances/ZINC000100071256
eMolecules	476513	https://www.emolecules.com/cgi-bin/more?vid=476513

PubMed

Title	Date	PubMed
Therapies for the treatment of abnormal uterine bleeding.	2001 Dec	12112970
Dental extractions in patients maintained on oral anticoagulant therapy: comparison of INR value with occurrence of postoperative bleeding.	2001 Dec	11829234
Possible role of plasminogen activator in the occurrence of profuse watery rhinorrhea after topical application of epinephrine to the nasal mucosa.	2001 Dec	11826693
Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins.	2001 Dec	11734579
The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding.	2001 Dec 1	11788179
Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery.	2001 Dec 1	11738071
Influence of Helicobacter pylori infection and cetraxate on gastric mucosal blood flow during healing of endoscopic mucosal resection-induced ulcers.	2001 Nov	11903737
The use of technologies to decrease peri-operative allogenic blood transfusion: results of practice variation in Israel.	2001 Nov	11729574
Blood conservation with tranexamic acid in total hip arthroplasty: a randomized, double-blind study in 40 primary operations.	2001 Oct	11728069
Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery.	2002	12381219
Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII.	2002	12214734
Danazol for heavy menstrual bleeding.	2002	12076401
Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding.	2002	11869575
Tranexamic acid in patients with hemoptysis.	2002 Apr	12118485
Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time.	2002 Apr	11943936
Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect.	2002 Apr	11907171
Is the kaolin or celite activated clotting time affected by tranexamic acid?	2002 Aug	12173818
Differential effects of aprotinin and tranexamic acid on endotoxin desensitization of blood cells induced by circulation through an isolated extracorporeal circuit.	2002 Aug	12154423
Pharmacokinetics of tranexamic acid during cardiopulmonary bypass.	2002 Aug	12151929
Differences between neonates and adults in carbohydrate sequences and reaction kinetics of plasmin and alpha(2)-antiplasmin.	2002 Feb 1	11927131
Tranexamic acid in hereditary hemorrhagic telangiectasia.	2002 Feb 7	11832543
Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.	2002 Jan	11807648
Purification and characterization of a novel esterase promising for the production of useful compounds from Microbacterium sp. 7-1W.	2002 Jan 10	11814667
[Tranexamic acid reduces blood loss and the need of blood transfusion after knee arthroplasty].	2002 Jan 14	11816327
Oral surgery in patients undergoing oral anticoagulant therapy.	2002 Jan-Feb	11788810
[Pulmonary embolism (PE) associated with urological surgery and angiography].	2002 Jul	12174640
[Contribution of Japanese researchers to progress in the field of hematology in the last 100 years: Congenital deficiency of alpha2-plasmin inhibitor].	2002 Jul 10	12187678
Rendu-Osler-Weber disease: experience with 56 patients.	2002 Jul-Sep	12402665
Menorrhagia.	2002 Jun	12230783
Clinical management of hereditary angio-oedema in children.	2002 Jun	12144636
Hemostatic effects of tranexamic acid in elective thoracic aortic surgery: a prospective, randomized, double-blind, placebo-controlled study.	2002 Jun	12063454
Re: Webster K, Wilde J. Management of anticoagulation in patients with prosthetic heart valves undergoing oral and maxillofacial operations. Br J Oral Maxillofac Surg 2000; 38: 124-126.	2002 Jun	12054729
Primary intestinal and thoracic lymphangiectasia: a response to antiplasmin therapy.	2002 Jun	12042562
Acute myocardial infarction after oral tranexamic acid treatment initiation.	2002 Jun	12036532
Acquired factor VIII inhibitors as a cause of primary post-partum haemorrhage.	2002 Jun 10	12039476
[Continuous infusion of recombinant activated factor VII during and after elbow arthroplasty in a hemophilia A patient with inhibitors].	2002 Mar	11979750
von Willebrand's disease: an important cause of dysfunctional uterine bleeding.	2002 Mar	11914650
Does tranexamic acid reduce desmopressin-induced hyperfibrinolysis?	2002 Mar	11882828
The two-domain NK1 fragment of plasminogen: folding, ligand binding, and thermal stability profile.	2002 Mar 12	11876638
Development of novel topical tranexamic acid liposome formulations.	2002 Mar 20	11879740
Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia.	2002 May	12144537
Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group.	2002 May 20	11992774
[Familial study of factor XI deficiency. Presurgical prophylactic treatment with desmopressin plus antifibrinolytics].	2002 Oct	12392675
Impact of hematocrit value after coronary artery surgery on perioperative myocardial infarction rate.	2002 Oct	12375180
Successful treatment of acute promyelocytic leukaemia during pregnancy.	2002 Oct	12358893
Mast cell-derived VEGF enhances the passage of IgE FE-3 through the rat aortic endothelial cell monolayer.	2002 Sep	12373001
Tranexamic acid reduces bleeding and the need for blood transfusion in primary myocardial revascularization.	2002 Sep	12238832
A comparison of clinical assessment with ultrasound in the management of secondary postpartum haemorrhage.	2002 Sep 10	12206921
Effect of fibrin sealant composition on human neutrophil chemotaxis.	2002 Sep 5	12115473
Safety and efficacy of methods for reducing perioperative allogeneic transfusion: a critical review of the literature.	2002 Sep-Oct	12237729

Patents

Sample Use Guides

In Vivo Use Guide

1,300 mg (two 650 mg tablets) three times a day (3,900 mg/day) for a maximum of 5 days during monthly menstruation

Route of Administration: Oral

In Vitro Use Guide

0.03 mg/mL Tranexamic acid reduced the fibrinogen fall induced by t-PA 20 nM from 43% to 14%.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:56:25 GMT 2023` Edited by `admin` on `Sat Dec 16 16:56:25 GMT 2023`
Record UNII	6T84R30KC1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TRANEXAMIC ACID

Official Name

English

TRANEXAMIC ACID [USP MONOGRAPH]

Common Name

English

TRANEXAMIC ACID [USP-RS]

Common Name

English

TRANS-4-(AMINOMETHYL)CYCLOHEXANECARBOXYLIC ACID

Systematic Name

English

CYCLOHEXANECARBOXYLIC ACID, 4-(AMINOMETHYL)-, TRANS-

Systematic Name

English

CYCLO-F

Brand Name

English

tranexamic acid [INN]

Common Name

English

RP-18429

Code

English

AMCHA

Common Name

English

TRANEXAMIC ACID [USAN]

Common Name

English

TRANSAMIN

Brand Name

English

LYSTEDA

Brand Name

English

NSC-291305

Code

English

TRANEXAMIC ACID [USP IMPURITY]

Common Name

English

TRANEXAMIC ACID [ORANGE BOOK]

Common Name

English

HAEMATRIX

Brand Name

English

CYCLOCAPRON

Common Name

English

CL65336

Code

English

TRANEXAMIC ACID [MART.]

Common Name

English

CL-65336

Code

English

CYKLOKAPRON

Brand Name

English

TRANS-AMCHA

Code

English

TRANEXAMIC ACID [INCI]

Common Name

English

ESPERCIL

Brand Name

English

TRANEXAMIC ACID [VANDF]

Common Name

English

TRANEXAMIC ACID [EP MONOGRAPH]

Common Name

English

TRANEXAMIC ACID [JAN]

Common Name

English

LB1148

Code

English

CYCLOKAPRON

Common Name

English

Tranexamic acid [WHO-DD]

Common Name

English

TRANEXAMIC ACID [MI]

Common Name

English

FEMSTRUAL

Brand Name

English

TRANS AMCHA

Code

English

RIKAVARIN

Brand Name

English

Classification Tree Code System Code

LIVERTOX

988